Recombinant humanized anti-ST2 monoclonal antibody

重组人源化抗ST2单克隆抗体

Report date: 2023/02/15 20:00:47

Base Information

Drug NameRecombinant humanized anti-ST2 monoclonal antibody
Drug Alias Name9MW19119-MW19119MW-19119-MW-1911
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-1 receptor-like 1 inhibitors
TargetsInterleukin-1 receptor-like 1
Therapy Area/IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A